MINDY4 and cancer: Although additional studies with human tissue are also required to assess feasibility, these results suggest that FAM188B overexpression could be used as a predictive biomarker for cancer diagnosis, and suggests that inhibiting FAM188B activity could be utilized as the putative target of cancer progression.